1-3 of 3
Niki Karachaliou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR005: Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis

Xiuning Le, Tae Min Kim, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jinji Yang, Marie Wislez, Cheng Huang, Chong Kim Liam, Julien Mazieres, Lye Mun Tho, Hidetoshi Hayashi, Nguyen Nhung, Puey Ling Chia, Fillippo De Marinis, Jo Raskin, Qinghua Zhou, Giovanna Finochhiaro, Daniel Tan, Sabine Brutlach, Aurora O'Brate, Svenja Adrian, Karin Berghoff, Barbara Ellers-Lenz, Niki Karachaliou, Yi-Long Wu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): PR005.
https://doi.org/10.1158/1535-7163.TARG-23-PR005
Published: 01 December 2023
View article titled, Abstract PR005: Tepotinib + osimertinib in <em>EGFR</em>-mutant NSCLC with <em>MET</em> amplification following first-line osimertinib: INSIGHT 2 primary analysis
Journal Articles

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (7): 833–843.
https://doi.org/10.1158/1535-7163.MCT-22-0537
Published: 05 July 2023
View article titled, The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations
Open the PDF for The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations in another window
Journal Articles

Abstract C41: BRAFV600 serum/plasma analysis: Predictive value of survival in melanoma treated with BRAF inhibitors.

Maria Gonzalez Cao, Salvador Martin Algarra, Eva Muñoz, Clara Mayo de las Casas, Jose Luis Manzano, Javier Cortes, Miguel Angel Molina-Vila, Jose Pablo Berros, Leticia De Mattos-Arruda, Miguel Sanmamed, Alvaro Gonzalez, Carlos Alvarez, Niki Karachaliou, Rafael Rosell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C41.
https://doi.org/10.1158/1535-7163.TARG-13-C41
Published: 01 November 2013
View article titled, Abstract C41: BRAFV600 serum/plasma analysis: Predictive value of survival in melanoma treated with BRAF inhibitors.